Surgical resection of solid tumors is currently the gold standard and preferred therapeutic strategy for cancer. Chemotherapy drugs also make a significant contribution by inhibiting the rapid growth of tumor cells and these two approaches are often combined to enhance treatment efficacy. However, surgery and chemotherapy inevitably lead to severe side effects and high systemic toxicity, which in turn results in poor prognosis. Precision medicine has promoted the development of treatment modalities that are developed to specifically target and kill tumor cells. Advances in in vivo medical imaging for visualizing tumor lesions can aid diagnosis, facilitate surgical resection, investigate therapeutic efficacy, and improve prognosis. In particular, the modality of fluorescence imaging has high specificity and sensitivity and has been utilized for medical imaging. Therefore, there are great opportunities for chemists and physicians to conceive, synthesize, and exploit new chemical probes that can image tumors and release chemotherapy drugs in vivo. This review focuses on small molecular ligand-targeted fluorescent imaging probes and fluorescent theranostics, including their design strategies and applications in clinical tumor treatment. The progress in chemical probes described here suggests that fluorescence imaging is a vital and rapidly developing field for interventional surgical imaging, as well as tumor diagnosis and therapy.
Introduction
Cancer is an extremely aggressive disease that involves uncontrolled cell growth and cell division. The incidence and death rate associated with cancer remain high, 1 and the mechanisms of the development and recurrence of tumors in humans are still not yet fully understood. 2 Therefore, cancer therapy faces huge challenges in modern medical technology. Precise detection of tumors should be the first consideration. The primary challenge for the diagnosis and treatment of tumors is finding effective ways to discriminate the boundaries between the tumor and healthy surrounding tissue at the cellular level. Early diagnosis and treatment of a tumor can increase the survival rate to 90%. However, a precancerous lesion has a small volume and its morphology is atypical. Therefore, the lesion is difficult to identify with the naked eye. Technologies that can indicate the molecular boundary between tumor and healthy tissue are necessary to precisely identify diseased tissue and exploit the unique characteristics of tumors. Traditional clinical approaches of surgery, radiotherapy, chemotherapy, and immunotherapy need to be further improved because untargeted therapies can damage both normal cells and cancerous cells, thereby causing serious side effects and poor quality of life and prognosis. Therefore, accurate diagnosis of the tumor is required before starting therapy.
It seems likely that bioimaging technologies will meet this challenge. To date, in vivo medical imaging has made great advances in locating and discriminating tumor lesions as a result of developments in the engineering of imaging devices and the chemistry of imaging probes. 3 Several imaging diagnostic technologies have been applied in clinical medicine to reveal underlying disease and to assess prognosis and treatment, including magnetic resonance imaging (MRI), X-ray radiography, computed tomography (CT), positron emission tomography (PET), ultrasonography (US), and optical imaging. However, novel imaging tools with high sensitivity are urgently required because of the relatively low concentrations of target analytes in vivo. Traditional imaging modalities like CT, MRI, and US lack sufficient specificity and sensitivity, which can be attributed to background tissue noise, tissue metabolism, and the limited resolution and depth of signal penetration. PET is highly sensitive, but widespread application of this imaging modality is limited by its poor spatial and temporal resolution and the stringent safety regulations for radioactive compounds. 4 Compared with the conventional strategies of CT, MRI, and radioisotope imaging, an optical-based imaging approach can increase the target-to-background ratio by employing optical probes with unique features of (1) simultaneous multicolor imaging and (2) signal activation in the tumor. Therefore, optical imaging, such as fluorescence and bioluminescence imaging, offers the promise of accurate tumor diagnosis through noninvasive, real-time, and high-resolution imaging. Fluorescence bioimaging as a technique to visualize specific organelles in live cells [5] [6] [7] [8] [9] [10] and whole animals 11, 12 has become a powerful supporting tool for biological research, [13] [14] [15] [16] and even for clinical utilization such as in the emerging field of fluorescence-guided surgery. [17] [18] [19] [20] [21] Additionally, fluorescence bioimaging can capture specific molecular information on tumor structure and tumor metabolism. Fortunately, these probes are also low cost, non-radioactive, simple and quick to use. In particular, near-infrared (NIR) fluorescence bioimaging probes with NIR absorption and emission profiles can
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The other challenge for tumor therapy is how to improve the drug therapeutic efficacy with minimum side effects due to the nonspecific distribution of small molecular drugs in vivo. Undoubtedly, the rapidly growing class of chemotherapeutic drugs has achieved clinical success. However, the severe side effects of many drugs, including poor bioavailability, rapid blood/renal clearance, nonselective accumulation, uncontrollable drug release, bone marrow depression, severe multidrug resistance, and gastrointestinal disorders, have decreased the drug efficacy and caused tremendous pain to patients. The new nano-carriers that have rapidly emerged as drug delivery systems may overcome these limitations. [30] [31] [32] [33] [34] [35] [36] [37] [38] The drug delivery mechanism of nano-carriers depends on enhanced permeability and retention (EPR) effects. The anticancer drugs are either conjugated to the nano-carriers or packaged as nanocapsules. These combinations demonstrate better tumor penetration and controllable drug release at the target site compared with free drugs. [39] [40] [41] However, these conjugates have several disadvantages that cannot be ignored, such as the potential cytotoxicity of the heavy metal component or surface-coated materials, high cost, and difficulties in reproducibility and quantification. 42, 43 Compared with nanoparticle-based therapeutic agents, small molecular fluorescent probe-based therapeutic agents are becoming preferred chemotherapeutic candidates. 3, [44] [45] [46] [47] [48] [49] [50] These small fluorescent theranostic agents exhibit improved photophysical properties and can be easily modified by chemical synthesis. 51, 52 The structural architecture of these systems is often relatively simple and compact: a desirable fluorophore, a tumor targeting ligand, and a masked antitumor drug. The intact theranostic agent is delivered through the circulation to accumulate in the tumor through the action of the targeting ligand. After being triggered to release drug in situ, the fluorophore emits fluorescence for monitoring of pharmacokinetics, tumor therapy, and tumor prognosis (Fig. 1) .
In this review, we describe the entities that have been elegantly established to date, and aim to provide an up-to-date and concise overview of the design, application, and development of small molecular-weight fluorescent imaging agents and fluorescent theranostics for tumor diagnosis and therapy. We summarize the criteria governing the choice of the targeted receptor, modification of the targeting ligand, employment of the conjugating linker, utilization of the fluorophore, and optimization of the therapeutic drug. We discuss the strategies for integrating a targeting ligand with a suitable fluorophore and the desired linker-cleavage chemical reaction for selective release of the masked cytotoxic drug after endocytosis into tumor cells. We also address the issue that the development of fluorescent imaging agents is currently limited by the availability of NIR fluorophores.
Fluorescent probes for tumor diagnosis
The early diagnosis of preinvasive and metastatic tumor cells in patients is critical for the success of tumor therapy and improvement of survival rates. The fluorescence bioimaging approach, which is emerging as a promising non-invasive, real-time, and high-resolution modality, can be employed for the early diagnosis of tumors. Fluorescent signals can provide molecular information on tumor tissues that is related to the tumor anatomical structure and metabolism. There is an urgent need to establish stable, efficient, and safe multifunction fluorescence systems to accelerate the achievement of accurate and personalized medicine. A successful fluorescent probe must meet several requirements for medical imaging, including wavelength, brightness, biostability, photostability, specific tissue accumulation, and pharmacokinetics. Conventionally, one approach is to simply and directly conjugate the fluorophore with a ligand that can bind to a certain cellular surface receptor: a so-called active imaging probe (Fig. 2) . The imaging mechanism relies on accumulation and retention of the probe at the target site as a contrast agent. This approach is helpful for tumor imaging, but the non-bound probe must be quickly cleared from the circulation via excretion. An activatable imaging probe can be employed to achieve highly specific delivery; this type of probe is only activated within the targeted tumor cells, for example by a tumorspecific enzyme. Such probes are non-fluorescent or weakly fluorescent in the unactivated state, but become strongly fluorescent after activation by the relevant molecular trigger. Thus, the target-to-background ratio is higher than that of active probes. The activation mechanisms of activatable probes mainly depend on enzyme digestion and quenching effects. After removal of the quencher moiety, the released fluorophores will immediately emit fluorescence (Fig. 2) . However, the fluorescent probes that are currently employed in intraoperative imaging systems for clinical fluorescence imaging are untargeted fluorophores including indocyanine green, 53 methylene blue, 54 5-aminolevulinic acid, 55 and fluorescein. 56 In this section, we classify these probes according to their conceived structures and functions.
NIR imaging fluorophores
Near-infrared (NIR) light can penetrate tissue more deeply and minimize the interference from background autofluorescence, which greatly facilitates in vivo imaging of the molecular processes. [22] [23] [24] [57] [58] [59] However, suitable fluorophores for tumor imaging must possess good hydrophilicity, stable photostability, high quantum yield, and excellent sensitivity in biological systems. Recent developments in cyanine dyes, squaraine, phthalocyanines, porphyrin derivatives, and BODIPY dyes have made them good candidates for tumor imaging (Fig. 3 ). Shi and Chung et al. identified a class of NIR fluorescence heptamethine cyanines (1-3) for tumor imaging. 60, 61 These small molecular dyes could be taken up and accumulated in tumor cells without requiring chemical conjugation with tumorspecific targeting ligands. The recognition mechanism was mediated by hypoxia-induced HIF-1a and specific organic anion transporting polypeptides (OATPs). This simple and direct strategy had no limitation to specific tumor cell types. The unique properties of 1 for selective imaging of the sentinel lymph node (SLN) in animals are very important because the SLN is the first barrier that prevents tumor cell metastasis from the lymph node. Real-time images from the injection site toward the SLN were achieved within 5 min, and the retention time could be up to 2 weeks. After conjugation of 2 with a positron-emitting radionuclide, the NIR dye 4 showed improved deep-tissue tumor detection with fluorescence imaging and PET/CT scans. 62 The above NIR dyes can be actively taken up and accumulated in cancer cells within 30 min. In vivo NIR imaging was achieved over a period of 24 h. The fluorescence emission that lies in the first near-infrared window (NIR-I; 650-900 nm) is far superior to visible wavelengths, but a fluorophore that emits within the second nearinfrared window (NIR-II; 1000-1700 nm) exhibits a greater improvement in imaging quality, such as decreased tissue autofluorescence, reduced photon scattering, and low levels of photon absorption. [63] [64] [65] [66] However, NIR-II fluorophores are often constrained by slow metabolism and long retention in the reticuloendothelial system. Hong et al. synthesized a soluble NIR-II emitting probe (5) for imaging the mouse lymphatic vasculature and sentinel lymphatic mapping near the tumor. 66 The fluorescent signal in 4T1 xenograft tumors was observed within 10 min after intradermal injection of 5-PEG. The probe 5-PEG was excreted through the kidneys within 24 h. Dye 5 also allowed targeted imaging of tumors in vivo when conjugated with an antiepidermal growth factor receptor (EGFR) antibody.
Hoffman et al. reported a chiral NIR porphyrazine (6) for accumulation in tumor cells. 67 The porphyrin derivative was composed of four bridged pyrrole subunits linked through nitrogen atoms. Compound 6 was taken up by cells into the lysosomes through low-density lipoprotein (LDL) receptor-mediated endocytosis. LDL is preferentially associated with highly proliferative tumor cells over normal cells, therefore this NIR fluorescent probe enabled excellent contrast imaging between tumor and surrounding tissue. In vivo studies revealed that 6 was preferentially taken up and retained in MDA-MB-231 human breast cell xenografts in mice. The retention of 6 in the tumors continued to increase up to 48 h after injection. A chemical compound with well-balanced charge would result in a more hydrophilic molecule with low non-specific targeting properties. Frangioni et al. introduced zwitterionic properties into NIR fluorophores to improve the signal-tobackground ratio for diagnostic and therapeutic applications. 68 Conjugates of the zwitterionic heptamethine indocyanine with cyclic peptide cyclo(RGD-yK) (7a-c) showed good behaviors in vitro for cell binding assays, histology, and immunoblotting and in vivo for xenograft tumor targeting and image-guided surgery.
Real-time intraoperative melanoma detection was achieved 4 h after intravenous injection into mice. A real-time intraoperative thrombus could be detected at 30 min.
Accidental transection or injury of nerves leads to significant morbidity of numbness, pain, or paralysis. Choi et al. evaluated an oxazine derivative (8) to navigate peripheral nerve structures in rats and swine. 69 The pharmacokinetic data suggested that the targeted fluorophore rapidly penetrated and was retained in nerves. The fluorescent labeled nerve was clear enough for discrimination for 3-4 h during complicated nerve surgery. The dye provided a nerve-targeted signal in the brachial plexus, sciatic nerve, and recurrent laryngeal nerve for up to 12 h after a single intravenous injection.
Probes integrating tumor-targeting ligands
Tumor targeting capability of fluorescent imaging probe is crucial for the accurate diagnosis of tumors. Common strategies for targeting ligand-based imaging probes involve exploitation of certain cell surface receptors that are overexpressed in cancerous cells (Fig. 2 ). There are a number of ligands (e.g., small molecules, peptides, proteins, antibodies, and aptamers) with a high intrinsic affinity for tumor targets that can be considered in the design of imaging probes. The probe is targeted to tumor cells through conjugation of a certain ligand, which accordingly reduces the delivery to normal cells and the associated collateral toxicity. Such strategies involve direct conjugation between the desirable fluorescent dyes and the ligands to produce a suitable imaging probe. This type of fluorescent probe can be targeted and bind to the tumor, while surplus probe will be excreted from the blood circulation. In this regard, an activatable imaging probe has the potential to further improve the signal-noise ratio. [84] [85] [86] [87] The design strategy for these optimized candidates was based on a rhodamine-derived fluorophore with selective COX inhibitors (Fig. 4) . In vitro experiments in 1483 head and neck squamous cell carcinoma (HNSCC) cells showed that compound 14 localized at the perinuclear regions of membraneous structures that appeared to be endoplasmic reticulum or Golgi. Lipopolysaccharide-activated RAW264.7 macrophages showed stronger fluorescence labeling due to immunological stress. These probes showed preferential accumulation in inflammatory lesions and tumors. Inflammation was induced with carrageenan in C57BL/6 mice and images were acquired 3 h after injection of the probes. The probes were then employed to image human tumor xenografts. Levels of fluorescence in the tumor required 3 h to reach near maximal levels and remained relatively high for at least 24 h. The authors also summarized the structureactivity relationship (SAR) effects between fluorophores and linkers. 85 The SAR study revealed that indomethacin conjugates were superior COX-2-targeted agents compared with other carboxylic acid-containing nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective inhibitors. The 2 0 -trifluoromethyl analog of indomethacin is a potent and selective COX-2 inhibitor. The same group synthesized and evaluated the fluorescence imaging probe 15 with improved ability to inhibit COX-2 in inflammatory tissues and human tumor xenografts. 86 Kinetic analysis revealed that 15 was a slow and tightly binding inhibitor of COX-2. Application of the NIR COX-2-targeted probe 15 could improve imaging signal-to-noise in cancer detection. Probe 15 exhibited selective and potent COX-2 inhibition of purified protein and in human cancer cell lines. Time course imaging studies conducted from 3 h to 7 days post-injection showed a gradual decrease of the fluorescent signal in 1483 HNSCC tumors. Peng et al. developed two-photon activatable fluorescent probes 16-19 for imaging COX-2 in cells and in vivo. [88] [89] [90] [91] All of these free probes existed in the folded state. This molecular configuration led to quenching of fluorescence due to photoinduced electron transfer (PET) between the fluorophores and the inhibitor of COX-2. Strong fluorescence would be emitted after binding of the probe to COX-2. The imaging probe 16 could target the Golgi apparatus of tumor cells. 88 It stained cancer cells within 0.5 h and fluorescence intensity remained almost unchanged in cells for at least 6 h. This probe allowed imaging of sarcoma 180 tissue slices at a depth from 0 to 650 mm. The enzyme COX-2 is expressed at low levels (o0.085 mg mL
À1
) as a monomer in inflammatory lesions. Each COX-2 monomeric unit is composed of three distinct structural domains. However, in tumor cells and tumor tissues COX-2 is expressed at high levels (40.085 mg mL
) and exists as a homodimer. The binding site of enzyme inhibitors is located at the end of a hydrophobic cavity. Peng et al. improved their probe (17) for a sensitive fluorescence response to environmental changes. 89 The fluorescence of 17 was ''turned on'' in both inflammation and cancer but the fluorescent emission was quite different. Moreover, cancerous tissues, inflamed tissues, and normal tissues could be discriminated in vivo by the naked eye. Probe 18 afforded high sensitivity and selectivity for COX-2 with a detection limit of 1.0 nM. 90 Probe 19 was a COX-2-specific NIR fluorescent probe 91 that could be directly applied to native polyacrylamide gel electrophoresis analysis and in-gel fluorescence analysis. This utilization facilitated rapid and sensitive screening of cancer cells without the need for a time-consuming enzymelinked immunosorbent assay (ELISA).
C. Folate receptor. Folate is essential for the proliferation and maintenance of all cells. Folate has a high affinity for its cell surface folate receptor (FR, K d : 10 À10 ). 92 The FR is primarily expressed on the healthy apical surface of polarized epithelial cells where it does not readily encounter folate from the bloodstream. 93 Once malignant transformation occurs, these apically restricted receptors will become accessible to folate because 93 This probe could be visualized in peritoneal, subcutaneous, and metastatic murine tumor models with 2 h intravenous administration. Folate receptor-mediated transcytosis could not be exploited to deliver this folate conjugate into the brain. 94 Tumor masses exhibited significantly more fluorescence than adjacent normal tissues regardless of autofluorescence of noninjected controls. Excretion of the fluorescein conjugate from non-targeted tissues was achieved mainly through the kidneys within 2 h. Tumor nodules less than 1 cm in size could not be accurately detected with either computer tomography or ultrasound, but the fluorescent probe could locate malignant lesions smaller than 0.5 mm with appropriate optical instrumentation. The overexpression of the folate receptor in 90-95% of epithelial ovarian cancers prompted investigation into the use of this probe in intraoperative specific fluorescence navigation to improve the prognosis of patients with ovarian cancer. 20 Further development of a near-infrared fluorescent probe (21) allowed identification of more deeply seated tumors based on the stronger penetration properties of near-infrared dye IR-783 compared with fluorescein. 20, 49, 95 Low et al. also synthesized a fluorescent folate conjugate (22) to label the disulfide bond-reducing process in endosomal compartments. 96 The approach adopted was to directly link folate to two fluorescent dyes via a disulfide bond, which engaged in fluorescence resonance energy transfer. Reduction of the disulfide bond resulted in a change in fluorescence from red to green. It was observed that disulfide reduction began in the endosomes and occurred with a half-time of 6 h after folate-FRET endocytosis. Choi et al. developed a folate receptor-specific probe (23) for NIR fluorescence imaging of ovarian tumors in vivo. 97 The probe was synthesized by conjugating folate to the ATTO655 fluorophore via a cathepsin B-cleavable peptide spacer. The fluorescence emission from the fluorophore was effectively quenched by folate. After specific uptake into SKOV3 cells, the tumor-associated cathepsin B enzymes subsequently activated NIR fluorescence emission by cleaving the spacer. Assessment of the tumor targeting of probe 23 in a xenograft mouse model of ovarian cancer showed that fluorescence images could be obtained after 3 h post-injection.
D. Glut5 transporter. Glut transporters are a family of transmembrane proteins that transport sugars such as glucose, fructose, and galactose across the cell membrane. They are expressed in different types of tumor tissues but have distinct substrates. 98 Tumor cells need to overexpress at least one Glut transporter to meet their high levels of energy consumption. Glut5 is a fructose-specific transporter that is expressed at high levels in breast cancer cells but is not dominantly expressed in normal breast cells. 99 To achieve molecular differentiation between cancerous and normal breast cells, Gambhir et al. synthesized two fructosebased fluorescent probes using 7-nitro-1,2,3-benzoxadiazole (24a) and cyanine5.5 dye (24b) as fluorophores, respectively. 98 Evaluation of the first metabolic pathway of fructose showed the involvement of hexokinases, which could phosphorylate fructose only in the breast cancer cell lines. On the basis of this result, the fluorophore labeling site was chosen in the C-1 position of fructose. The uptake of probe 24a was dependent on the presence of the fructose-specific transporter Glut5. Probe 24b with the very bulky fluorophore cyanine5.5 resulted in nonspecific accumulation in breast cancer cells (Fig. 5 ).
E. Cholecystokin receptor. The cholecystokin 2 receptor (CCK2R) belongs to the family of membrane G protein-coupled receptors. The CCK2R and its tumor-specific splice variant CCK2i4svR are overexpressed in tumors of the pancreas, medullary thyroid, lung, breast, ovary, gastrointestinal tract, and colon. [100] [101] [102] [103] [104] [105] [106] The CCK2R has normal organ distributions in the central nervous system and gastrointestinal tract.
Low et al. reported a tumor-specific nonpeptidic conjugate (25) that could target the CCK2R and its splice variants for use in fluorescence imaging. 107 The 6 -Ala-Tyr-Gly-TrpMet-Asp-Phe-amid via a hydrophilic linker. 108 The binding assay demonstrated a high binding affinity for CCK2R-expressing A431 cells. After intravenous injection of the probe, a fast and longlasting accumulation in tumors was observed. CCK2R expression was clearly identified by fluorescence imaging in the A431/CCK2R xenografts at 8 h post-injection.
F. Carbonic anhydrase IX. Carbonic anhydrases are a family of transmembrane zinc metalloenzymes that exist in 16 different isoforms. These isoforms are distributed in different subcellular organelles where they play catalytic roles and are susceptible to their own specific inhibitors. Carbonic anhydrase IX (CAIX) is normally expressed in the stomach and gallbladder epithelia. However, CAIX can be used as a marker of hypoxia because of its overexpression in solid tumors such as glioblastoma, colorectal, and breast [109] [110] [111] and is therefore a potential tumor target.
Neri et al. designed and characterized a series of smallmolecule fluorescence conjugates (27a-c) targeting CAIX. 112 These acetazolamide-based fluorophore conjugates were found to preferentially target CAIX-expressing tumor cells. Compound 27c was used to evaluate biodistribution in a mouse model. The results showed that accumulation of 27c in the tumor was rapid and efficient at 1 h post-injection; however, the short retention time in the tumor (residence half-life t 1/2 E 1 h) suggested that the bivalent inhibitor acetazolamide against CAIX might result in improved CAIX binding affinity compared with its corresponding monovalent counterpart. Neri et al. synthesized monovalent and bivalent acetazolamide fluorescence conjugates (28a-b) and tested their binding to tumor cells. 113 Their results
showed that the bivalent conjugate 28b efficiently accumulated in CAIX-expressing SKRC52 kidney xenograft tumors with a retention time (424 h) longer than that of the corresponding monovalent conjugate 28a.
G. Poly(ADP-ribose) polymerase-1. Poly(ADP-ribose) polymerase-1 (PARP-1), a well-known DNA-binding enzyme, is expressed in human tumors due to a deficiency in DNA repair enzymes, rendering the tumor cells susceptible to the small-molecule PARP1 inhibitor olaparib. Weissleder et al. synthesized a fluorescent olaparib derivative (29) for single-cell and subcellular pharmacokinetic analysis in murine cancer models. 114 H. Sialic acids. Sialic acids are anionic monosaccharides located at the termini of cell surface glycans. These derivatives of N-acetylneuraminic acid are involved in host-pathogen interactions and cell-cell adhesions. Overexpression of sialic acids on the cell surface has been associated with metastatic potential in a broad spectrum of tumors, suggesting an enhanced metabolic demand for sialic acids by these tumor cells. 117, 118 Han et al. reported a 9-fluoresccinylthioureido-9-deoxy-Nacetylneuraminic acid (30) for high-performance detection of tumors through labeling of sialic acid. 119 Probe 30 could be transferred into the Golgi and metabolically incorporated into glycoproteins via a cellular sialylation pathway. The fluorescence View Article Online signal was observed in tumors within 20 min after administration. The off-target probe was quickly eliminated from the circulation. The tumor-to-organ fluorescence ratios remained high up to 10 h post-injection. Implanted H22 hepatocellular carcinoma in the liver could be clearly discerned for tumors with a diameter of 0.2-5 mm. However, the active imaging probe 30 suffered from ''always-on'' green fluorescence, which limited deep tissue penetration. Han et al. next presented a sialylated pH-activatable NIR probe 31 for fluorescence targeted tumor detection. 120 The sialic acid ligand provided effective tumor targeting in H22 hepatocellular carcinoma lesions and the NIR fluorophore underwent lysosomal pH-triggered isomerization to emit fluorescence. The micromilieu of solid tumors is hallmarked by acidic microenvironments due to the accumulation of lactic acid by glycolysis. Therefore, probe 31 displayed a high tumor-to-normal tissue signal contrast. The NIR signal was observed in nude mice 30 min after administration via the tail vein, and the signal could be retained for 144 h after injection. Additionally, 31 could effectively convert NIR light into cytotoxic heat to kill tumor cells, suggesting tumor-activatable photothermal therapy.
I. Alkylphosphocholine. Alkylphosphocholine derivatives (APCs) selectively accumulate in many solid tumor cells compared with normal cells. 121 APCs also show suppressive effects on tumor growth and extend survival. APCs target cellular and intracellular membranes, inhibit phosphatidylcholine biosynthesis, interfere with lipid transduction pathways, block the endoplasmic reticular transport of cholesterol, and ultimately disrupt cholesterol homeostasis and membrane lipid raft function. 122, 123 Kuo et al. developed two APC-based cancer-selective fluorescent probes CLR1501 (32) and CLR1502 (33) for discriminating tumors from normal brain tissue in fluorescence-guided glioma surgery. 123, 124 These two probes provided high tumorto-normal brain contrast in fluorescence discrimination with glioblastoma multiforme and glioblastoma stem cell-derived xenografts in mouse models. Moreover, 33 showed a superior tumor-to-brain fluorescence ratio compared with 5-aminolevulinic acid, which is the current standard for fluorescence-guided neurosurgery. The tumor fluorescence was readily detected with the indocyanine green fluorescence microscopy technique currently used in the clinic. 2.2.2 Peptides, proteins, and antibodies as tumor targeting ligands. Small molecular weight peptides are the preferred candidates as potential targeting ligands. 125 These peptides possess strong targeting capability as they easily penetrate the cell membrane; alternatively, cell-specific target delivery can be improved by facilitating receptor-mediated endocytosis. Peptides that block signal transduction or interfere with nuclear localization may also have therapeutic effects on tumors. Compared with larger antibodies or proteins, peptides are easily synthesized, effectively penetrate tissues, and are rapidly cleared from the circulation.
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A. IL-11 receptor. Interleukin-11 (IL-11) is a multifunctional cytokine in blood cells. The IL-11 receptor alpha-chain (IL-11Ra) is a member of the gp130-dependent receptor group (Fig. 6 ).
IL-11 and IL-11Ra are related to breast cancer development and progression and play crucial roles in bone metastasis of human breast cancer, which indicates poor prognosis. 126 Targeting of IL-11Ra-positive tumors has potential as a useful strategy for noninvasive imaging. Wang et al. developed a NIR fluorescence and single photon emission tomography (SPECT) dual-modality imaging probe (34) to improve the diagnosis and management of tumors. 127 The targeting moiety was the cyclic nonapeptide c(CGRRAGGSC), which showed a particular affinity for IL-11Ra, the radiotracer was radioisotope 111 In complexes, and the fluorescence signal generator was the cyanine dye IR-783. Dual-modality imaging of mice bearing subcutaneous MDA-MB-231 tumors demonstrated uptake of the imaging probe in the tumor 24 h after administration.
B. Vitronectin receptor. Integrins are a family of heterodimeric transmembrane proteins that behave as receptors for specific steric-configuration constrained extracellular ligands. 128, 129 Among these integrins, a v b 3 , the vitronectin receptor, plays important roles in tumor progression, angiogenesis, and metastasis. [129] [130] [131] [132] Vitronectin, which contains the arginine-glycine-aspartic peptide sequence (Arg-Gly-Asp, RGD), exhibits a high affinity for a v b 3 , providing a promising ligand for diagnostic imaging and a therapeutic target in tumors. Li et al. reported the synthesis and characterization of integrin a v b 3 -targeted peptide cyclo(Lys-Arg-Gly-Asp-Phe) [c(KRGDf)] labeled with NIR cyanine dyes Cy5.5 (35a) and IRDye800 (35b) for tumor imaging. 133, 134 These peptide-dye conjugates showed specificity for human Kaposi's sarcoma (KS1767) cells that overexpress a v b 3 . Tumors were clearly visualized after intravenous injection at a dose of 6 nmol per mouse. Dynamic fluorescence images obtained over a period of 20 min revealed that 35a was rapidly taken up by KS1767 tumors after intravenous injection. Blasberg et al. reported an IRDye 800CW-conjugated c(KRGDf) peptide that specifically targeted the overexpressed integrin receptors in murine RCAS-PDGF-driven/tv-a glioblastomas and two human orthotopic glioblastomas (U-87 MG and TS543). 135 The three tumor models exhibited different levels of integrin receptor upregulation. The conjugate could specifically bind the overexpressed integrin receptors in these glioblastomas and visualization of the tumor tissue and tumor margins could be achieved by NIR imaging.
Chen et al. used the RGD peptide cyclo(Lys-Arg-Gly-Asp-D-Tyr) [c(RGDyK)] as a targeting ligand to produce a sensitive and semiquantitative NIR fluorescence imaging probe 36.
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The conjugate could function as a specific ligand toward the a v b 3 integrin receptor in the human glioblastoma cell line (U87MG) and primary human brain capillary endothelial cells (HBCECs) that are known to overexpress a v b 3 integrin. In vivo three-dimensional imaging showed typical NIR fluorescence images of athymic nude mice bearing subcutaneous U87MG glioblastoma tumors after intravenous injection of optimized doses of 36. The tumor could be clearly discriminated from the surrounding tissue from 30 minutes to 24 h post-injection, with maximum contrast occurring about 4 h post-injection.
Additionally, Cy5.5-conjugated monomeric, dimeric, and tetrameric c(RGDyK) peptides (37a, 37b) were evaluated in subcutaneous U87MG glioblastoma xenograft models and were all suitable for integrin expression imaging. Forni et al. reported a NIR fluorescence RGD cyclic probe 39 for noninvasive detection of a v b 3 integrin-overexpressing tumors. 141 The targeting moiety was a functionalized cRGD peptide that preferentially bound the Mn-activated form of integrin, mediating rapid and extensive cell adhesion. The conjugate displayed a high binding affinity for a v b 3 integrin on human U-87 MG glioblastoma cells and their xenografts in nude mice. Probe 39 showed broad diffusion in most organs after injection, followed by a progressive increase up to 24 h with specific accumulation in tumors. The low expression of a v b 3 integrin on the C6 glioma cell line led to reduced specific accumulation in the tumor. The expression and retention of 39 The intense signal detected at the tumor site could be retained for more than 48 h.
C. Underglycosylated mucin-1 tumor antigen. Underglycosylated mucin-1 tumor antigen (uMUC-1) is one of the early hallmarks of tumorigenesis in a wide variety of tumors. 143 The EPPT peptide with the sequence AREPPTRTFAYWG targeting the uMUC-1 antigen was derived from the CDR3V b region of a monoclonal antibody. 144 Moore et al. developed a conjugate cyanine 7-EPPT peptide (41) for tumor imaging. 143 The hydrophilicity of the cyanine fluorophore was increased by introduction of a sulfonic moiety. Removal of the carboxylic acid group would eliminate the possibility of cross-linking with peptides/proteins during conjugation. NIR fluorescence imaging was obtained 24 h after injection of 41. The results showed specific accumulation in mice bearing human pancreatic adenocarcinoma CAPAN-2.
D. Epidermal growth factor receptor. The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein. Activation of the EGFR triggers the signal transduction pathways involved in regulating cellular proliferation, differentiation, and survival. [145] [146] [147] The EGFR is overexpressed in many tumor cell lines, and is associated with poor prognosis and high mortality. The epidermal growth factor (EGF) is one of the most important ligands for the EGFR.
Li et al. reported an EGF-Cy5.5 fluorescent probe (42) for the detection of the EGFR in human breast tumor xenografts. 148 The conjugate was conveniently synthesized from EGF and an NHS ester of Cy5.5. The selectivity of EGF-Cy5.5 for the EGFR was established by comparing the binding capability between EGFR-overexpressing MDA-MB-468 tumor cells and EGFRnegative MDAMB-435 tumor cells. NIR fluorescence in mice bearing MDA-MB-468 tumors was still detectable at 96 h after injection of 42 and the signal intensity returned to the background level at 192 h.
Basilion et al. developed a series of NIR probes 43a-d targeting the EGFR for imaging glioblastoma brain tumors in vivo. 149 The probes were synthesized by varying the length of the polyethylene glycol (PEG) spacer between the peptide GE11 (YHWYGYTPQNVI) and the fluorophore Cy5.5. The length of the linker critically affected the affinity of the probes for tumors. Probe 43b, which had one unit of PEG, had the highest apparent affinity for the EGFR in glioblastoma cells and could selectively localize at glioblastoma-derived orthotopic brain tumors. When tested in cultured cell lines that expressed different levels of the EGFR and in orthotopic brain tumors using fluorescence-mediated molecular tomography, the probe could distinguish different tumors expressing various levels of the EGFR.
E. Tyrosine phosphatase m. Receptor protein tyrosine phosphatase m (PTPm) protein transduces signals in response to cell adhesion and is highly expressed in the normal brain. Expression of full-length PTPm is downregulated in the most aggressive glial tumor, glioblastoma multiforme. 150 Brady-Kalnay et al.
verified that the extracellular fragment of PTPm is expressed in the human glioblastoma multiforme tumor margin but not in normal brain tissue. A series of peptides (SBK1-4) were linked to Texas Red, Cy5, and Alexa 750 fluorophores to recognize protein fragments of PTPm. [150] [151] [152] The SBK2 conjugate labeled the main tumor mass of an intracranial animal model of glioma as well as tumor cells at the margin. SBK2 could navigate the margin and recognize dispersing tumor cells up to 4 mm from the main tumor mass. The SBK2 conjugate rapidly accumulated in tumors within 10 minutes, and the fluorescent signal was retained for more than 180 min.
F. Chlorotoxin. Chlorotoxin (CTX) is a 36-amino acid peptide with four disulfide bridges that preferentially binds to glioma cells. 153 The molecular targets of CTX include a lipid raftanchored complex that contains matrix metalloproteinase-2 (MMP-2), membrane type-1 MMP, the transmembrane inhibitor of MMP-2, the glioma-specific chloride ion channel, and the ClC-3 chloride ion channel. 44 For intraoperative differentiation of tumor margins or small foci of cancer cells, Olson et al. developed a molecular imaging conjugate composed of CTX and Cy5.5. 154 The probe could delineate malignant glioma, medulloblastoma, prostate cancer, intestinal cancer, and sarcoma from adjacent non-neoplastic tissue. Specific binding to cancer cells was facilitated by MMP-2. The fluorescent signal was still higher in xenografts than in nonneoplastic tissue at 14 days after injection. The conjugate was concentrated in the kidneys and was excreted in urine. The Cy5.5 conjugation resulted in a mixture of mono-, di-, and tri-labeled probes because CTX contains three lysine residues. 155 Substitution of the lysines at positions 15 and 23 with either alanine or arginine would result in a Lys27 monolabeled peptide that retained the stability and in vivo half-life properties of CTX.
The half-life of the Cy5.5-labeled linear peptidic probe was 14 h, whereas that of Cy5.5-labeled cyclized chlorotoxin was 11 h. Kovar et al. developed and tested a targeted NIR probe CLTX-800CW for brain tumors in the mouse model ND2:SmoA1, which spontaneously develops medulloblastoma tumors. 156 Colocalization of hematoxylin and CLTX-800CW in cells at the tumor margin was distinctly visible. Specificity and functionality of the targeted probe for MMP-2-dependent tumor cell targeting were evaluated by examining cultured medulloblastoma, glioblastoma, lung carcinoma, and prostate carcinoma cell lines in a microplate assay. Butte et al. presented a NIR imaging probe BLZ-100, using a standard charge-coupled device (CCD) camera to visualize low levels of BLZ-100 binding to the tumors. 157 BLZ-100 exhibited a high affinity for glioma. After injection of BLZ-100 for 48 h, the orthotopic glioma tumors in mice were effectively discriminated from the surrounding normal brain tissue.
G. Endostatin. Endostatin, a 20 kDa C-terminal fragment of type XVIII collagen, is a potent inhibitor of angiogenesis, lymphangiogenesis, and cancer metastasis. 158 Endostatin can bind to a variety of receptors including the VEGF receptor, integrin, and glypicans. All of these receptors are associated with tumors. Camphausen et al. reported an endostatin-Cy5.5 conjugate for imaging tumor in vivo. 159 After injection into mice bearing Lewis lung carcinoma tumors, the conjugate selectively migrated to the site of the tumor. Injection of endostatin-Cy5.5 produced a nearinfrared fluorescent image within the tumors at 18 h and reached a maximum at 42 h after injection. Intravenous injection provided a peak emission at 3 h, and the fluorescent signal persisted until 72 h. Immunofluorescence imaging of tumor specimens confirmed the intratumoral binding site for endostatin at the tumor vasculature.
H. Macromolecules. Larger particles (usually with diameters o600 nm) can passively accumulate in tumor tissues because of the enhanced permeability and retention (EPR) effect caused by defects or gaps in the tumor vasculature. 160 Licha et al.
reported serum protein-dye conjugates consisting of transferrin (44a) or human serum albumin (44b) and the cyanine derivative for tumor imaging. 161 In contrast to 44b, the transmembrane mechanism of 44a in HT29 human colon carcinoma cells was mediated by receptor endocytosis. After intravenous injection of both compounds into HT29 tumor-bearing nude mice, maximum fluorescence intensities were reached after 6 h in tumor tissue. However, the contrast between tumor and normal tissue was significantly higher for 44a than for 44b at 24 h after injection. 44a produced fluorescence in viable tumor cells, whereas 44b fluorescence was observed along connective tissue.
I. Antibodies. Monoclonal antibodies (mAbs) usually have excellent antigen specificity and a higher binding affinity than peptides. 162 Fluorescently-labeled antibodies provide potential strategies to specifically target tumor cell-specific surface epitopes in vivo while avoiding off-target effects. 163 Thus, antibody-based fluorescence probes show great promise for broad applications in clinical medicine, such as cancer diagnosis, staging, and therapy response assessment. Cetuximab is an anti-EGFR antibody that selectively binds to the external domain of the EGFR with a high affinity. 164 Rosenthal et al. conjugated cetuximab with a fluorophore Cy5.5 for imaging HNSCC xenografts. 165 2 ) by bioorthogonal ''click'' ligation of trans-cyclooctene and tetrazine. 167 Next, the NIR fluorophore ZW800-1 was conjugated to Bs-F(ab) 2 for NIRF imaging of mice bearing U87MG subcutaneous xenografts. ZW800-Bs-F(ab) 2 showed excellent uptake in tumors and low background in non-target tissues. The probe could delineate the tumor contours and was useful for locating the tumor and guiding removal of the tumor foci and surgical margins. The fluorescence of indocyanine green (ICG) will be quenched upon binding to mAbs. After endocytosis and internalization, ICG dissociates from the targeting mAbs and the fluorescence emission is recovered. This property can be used to generate activatable probes. Kobayashi et al. Inappropriate activation of the mucosal immune system can lead to production of the proinflammatory cytokine TNF-a, which plays a pivotal role in the immunopathogenesis of Crohn's disease. The monoclonal antibody adalimumab exhibits a high affinity to human mTNF. Neurath et al. labeled the adalimumab antibody with an FITC fluorophore for in vivo imaging of mucosal immune cells in Crohn's disease during colonoscopy. 163 The response time of the probe was 10 min at room temperature. Ex vivo confocal imaging revealed specific fluorescence signals for the identification of mTNF-expressing mucosal cells in the inflamed tissue. They quantified the number of immune cells expressing mTNF and found that patients with high or low numbers of mTNF + immune cells showed high or low response rates to adalimumab therapy, respectively.
Hypoxia-mediated tumor imaging
Hypoxia is one of the features typically observed in malignant solid tumors in vivo. Two different biological responses, stabilization of hypoxia-inducible factor-1 (HIF-1) and accelerated bioreductive reaction, are induced by hypoxia. Tumor cells display an elevated level of reductive enzymes such as nitroreductase, DT-diaphorase, and azoreductase. Therefore, tumors can accelerate enzyme-catalyzed one-electron reduction to reduce specific functional compounds containing a nitro group, quinone group, and azo group. This renders these enzymes ideal targets for tumor cells in vivo. Several hypoxia-sensitive fluorescent probes have been developed. 174 Here, we summarize the fluorescent probes for potential tumor imaging.
A. Nitro group. Nitroreductase (NTR), which belongs to the family of flavin-containing enzymes, can reduce nitroaromatics to the corresponding amino derivatives in the presence of nicotinamide adenine dinucleotide (NADH). It is well known that the strong electron withdrawing nitro group can quench fluorescence when conjugated to fluorophores, while the fluorescence of fluorophores will return once the nitro group is reduced to the corresponding amine.
Qian et al. synthesized a series of nitro fluorescent probes for targeting hypoxia environments in solid tumors. 175 The NIR fluorescence probe (45) could be used to monitor NTR in A549 cells under normoxic conditions and different hypoxic conditions. 49 was also transferred into hypoxic A549 tumor-bearing mouse models via intratumoral injection. PET imaging confirmed that the A549 tumor in the murine model was a hypoxic tumor. Strong fluorescence in the hypoxic A549 tumor could be observed within 60 s, and this fluorescent signal lasted for more than 30 min. C. Azo group. The azo group is a fluorescence quenching group because of its ultrafast conformational change around the NQN bond after photoexcitation; when reduced by reductases under hypoxia this quenching process will be inhibited. Nagano et al. exploited azobenzene derivatives as hypoxia-sensitive moieties and developed a NIR fluorescent probe (52) for hypoxia detection. 185 The fluorescence increase was triggered by cleavage of the azo bond. The fluorescence regulation mechanism was Förster resonance energy transfer (FRET). After enzymatic reactions under hypoxic conditions, the fluorescence intensities of these probes reached a plateau within 10 min. These probes could distinguish hypoxia in MCF-7 breast cancer cells. Probe 52 could detect hypoxia in mice using an ischemia model of the mouse liver with a rapid in vivo fluorescence response within 1 min after vessel ligation. Hanaoka et al. conceived a further improvement to azobased hypoxia sensors. 186 They directly conjugated the azo group to per-rhodamine fluorophores and obtained two probes (53a and 53b). Once reduced under hypoxia, the two probes resulted in free fluorophores. The resultant colorimetric and fluorescent changes could be utilized to indicate different levels of hypoxia. Cellular hypoxia was observed under hypoxic conditions with a timedependent course. Probe 53a was localized in the mitochondria, whereas 53b was localized inside the lysosomes. In vivo imaging studies showed that 53a could visualize retinal hypoxia in a rat model of retinal artery occlusion.
Applications of theranostics in tumors

General strategies and activation mechanism
Fluorescent probes that integrate tumor-targeting ligands have successfully been used to identify and localize tumor masses in tumor diagnosis trials. The next focus is the enhancement of the drug therapeutic efficacy by improving the targeting function of small molecular drugs to achieve accumulation in tumor lesions. Conjugation of these diagnostic tools with small cytotoxic drugs generates a new synergistic system with simultaneous diagnostic and therapeutic capabilities; this field has been termed theranostics. Theranostic agents have the promise of regulating precisely when, where, and how a pharmaceutically active artificial compound is delivered to a single cell. The major features of small conjugate theranostics include targeted accumulation, improved pharmacokinetics, imaging ability, real-time information on treatment, and intraoperative guidance. Such agents can not only increase therapeutic efficacy, but also elucidate underlying disease mechanisms and allow pre-and post-treatment assessment. 50 The critical features of small conjugate theranostics design include the fluorescence manipulated mechanism, cytotoxic drug selection, regulation of prodrug release, and localization capability. Overall, theranostics aims to improve biodistribution, increase tumor targeting ability, reduce biotoxicity, and minimize side effects. Generally, a small molecular fluorescent conjugate therapeutic should be composed of four moieties: an imaging fluorophore, a chemotherapy drug, a targeting ligand, and an appropriate linker (Fig. 8) . These theranostic agents can show increased localization and therapeutic efficacy at the tumor site via the specific recognition of receptors that are overexpressed on the surface of tumor cells. After reaching the targeting site, the cleavable linkers are broken and the masked drugs are directly released for therapy. The cleavable linkers are required to behave as stable chemical bonds unless they are selectively activated by a variety of external stimuli signals, such as temperature, light, magnetic field, ultrasound, and electric current. More importantly, the ability to selectively cleave the linkers by endogenous disorder factors, such as biothiols, reactive oxygen and nitrogen species, acidic pH, intracellular redox potential, enzymes, and glucose is even more favorable for the treatment of disease. The requirements of fluorophores and targeting ligands are the same as those of the fluorescent probes used for tumor diagnosis. The fluorescence changes of the imaging fluorophores should illustrate the biodistribution of the therapeutics, View Article Online tumor lesions, and pharmacokinetics (Fig. 8) . Recently, small fluorescent conjugate therapeutics have been developed for tumor diagnosis and therapy. In this section, we discuss the latest developments in these theranostics according to the cleavable mode of the linkers, which essentially form the sluice for drug release and fluorescence emission.
Thiol-mediated modes
Glutathione (GSH) is the most abundant endogenous biothiol in cells. It participates in various cellular processes, including cell differentiation, cellular metabolism, antioxidant defense, and apoptosis. 187 Normal concentrations of GSH range from 1 to 15 mM depending on the cell type. 188 However, the intracellular GSH level is much higher in tumor cells than in normal cells. 189 The disulfide bond (-S-S-) can be cleaved via the reduction of free biothiols. 190 Therefore, GSH seems to be an ideal bioactivator for triggering therapeutics. A cytotoxic drug can be conjugated with a fluorophore via a disulfide linker to form a desired therapeutic agent with the specific capability to accumulate in tumor lesions. The therapeutic agent does not release the antitumor drug before it reaches the tumor cells because of the relatively low concentration of GSH in blood circulation and in normal cells (Fig. 9 ). Here, DOX was masterly chosen as both the prodrug and fluorophore, and folic acid was selected as both the targeting ligand and quencher for DOX. The theranostic agent 54a could be selectively activated by a high concentration of glutathione (GSH) in A549 cells via cleavage of the disulfide linker between DOX and folic acid, allowing monitoring of the theranostic agent's intracellular localization and migration before recovering its cytotoxicity. The control theranostic agent 54b confirmed the results. Treatment of 54a with GSH resulted in fluorescence activation within 3 h. The plasma stability of the disulfide linker in mice was 47 h (t 1/2 ). Time-dependent viability of A549 cells showed the high and sustained cytotoxicity of 54a. Gemcitabine, a commercial antitumor drug, principally functions as a strong inhibitor of a pyrimidine base in DNA replication or as an apoptosis inducer via an interaction with ribonucleotide reductase. Kim et al. reported the prodrug 55 as an NIR targeted drug delivery system. The theranostic agent included the targeting ligand folate, modified gemcitabine, and a Cy7 fluorophore conjugated with a cleavable disulfide linker. 192 Upon reacting with GSH, the prodrug 55 decomposed into an amino fluorophore derivative and released gemcitabine. Biotin is a B-group vitamin with an extreme affinity for avidin proteins. Biotin is a key micronutrient for cellular function and cell growth. Biotin uptake is much higher in rapidly growing tumor cells than in normal cells. Ojima et al. used biotin as a tumor targeting ligand in the design of theranostic agents utilizing different anticancer drugs and fluorophores. [196] [197] [198] The biotinylated fluorescein coupled with SB-T-1214 via the selfimmolative disulfide linker formed theranostic agent 59.
Therapeutics with disulfide bonds and targeting ligands. The folate receptor (FR) is a well-known tumor-associated receptor
Cleavage of the disulfide bond by endogenous GSH would release the anticancer drug and fluorescein. Fluorescent imaging demonstrated that theranostic agent 59 localized at the microtubules. This group developed a versatile platform that consisted of 1,3,5-triazine as the tripod splitter module, both SB-T-1214 and camptothecin as antitumor drugs, biotin as the tumortargeting moiety, and the disulfide linker. 199 The prodrugs 60a and 60b were delivered to cell lines that overexpressed the biotin receptor, such as MX-1, MCF-7, ID8, and L1210FR cells. After activation by GSH, 60a exhibited IC 50 values of 3.22-9.80 nM against all biotin receptor-positive cell lines, and 705 nM against biotin receptor-negative WI38 cells. Next, they adopted this strategy to report two tumor-targeting theranostic conjugates 61a and 61b. 200 The cytotoxic drug taxoid 3 was conjugated with a fluorine-labeled prosthetic (61a) or a fluorophore fluorescein (61b) via a disulfide bond. Once internalized into tumor cells, the disulfide bond was cleaved by endogenous biothiols and . 203 Cleavage of the disulfide bond occurred in the ER, releasing the active HJ inhibitor peptide2 drug and the fluorophore. SN-38 is a topoisomerase I inhibitor and the active ingredient in CPT11 (camptothecin), which is used as a therapeutic agent to treat various carcinomas. The potent antitumor drug SN-38 was connected to a biotinylated rhodol fluorophore through a cleavable disulfide bond linker. 204 The theranostic agent 65 displayed a 32-fold increase in the fluorescence intensity within 10 min after exposure to GSH. The prodrug was internalized effectively within biotin receptor-enriched cells by receptor-mediated endocytosis and showed targeted antiproliferative activity against biotin receptor-positive HeLa and A549 cells as a result of release of SN-38 within these cells (Fig. 10) . The antitumor efficacy of 65 was evaluated in vivo using a xenograft murine model created by subcutaneous inoculation with HeLa cells. Ex vivo optical and fluorescence imaging showed increased fluorescence of the tumor region compared with other organs, confirming the in vivo tumor targeting effect of the prodrug. The Shiga toxin receptor Gb3 is overexpressed on the surface of certain human cancers, including colorectal carcinoma. The cytotoxic drug SN-38 belongs to the class of camptothecin derivatives that inhibit topoisomerase I. Johannes et al. designed prodrug conjugates 66a, b, c, d to deliver the cytotoxic drug SN-38. 205 The disulfide linkage of these prodrugs involves two different spacers with different stabilities in the biological system.
One is based on an aromatic ring (66a,b) and the other on an aliphatic chain (66c,d). Conjugate 66b was too unstable to be used in vivo; however, conjugate 66d was completely stable over extended periods of up to 48 h in all media. Enzyme-linked immunosorbent assay (ELISA) analysis of 66d indicated that cleavage of the disulfide bond became detectable between 6 and 24 h and was essentially complete at 48 h. This slow release should sustain the continued presence of the active principle in dividing tumor cells, with the prodrug being otherwise rapidly cleared from the circulation. The disulfide bond of prodrug 66c was cleaved in the ER, which functions in cellular redox homeostasis. The ER was close to the nucleus, where the molecular target of hydrophobic SN-38 resides. In addition to folate and biotin, cyclic peptides are another type of effective tumor targeting ligand. These peptides contain an RGD (Arg-Gly-Asp) sequence, which can be recognized and internalized by a well-known tumor-associated receptor, a v b 3 integrin. a v b 3 integrin is highly expressed on several activated endothelial cells and plays a predominant role in tumor-induced angiogenesis and growth. Kim et al. reported a therapeutic agent 67 that allowed direct, fluorescence-based monitoring of targeted cellular uptake and release of the antitumor drug camptothecin. 206 The results of cellular experiments indicated that conjugate 67 bearing a cyclic RGD peptide targeting subunit was selectively internalized into U87 tumor cells via a v b 3 integrinmediated endocytosis. Disulfide bond cleavage occurred in the ER, permitting fluorescence changes of the naphthalimide moiety within 60 min.
Therapeutics without targeting ligands.
Although the targeting ligands facilitate internalization of the theranostic agents into tumor cells through receptor-mediated endocytosis, theranostic agents that directly conjugate fluorophores with anticancer drugs have also been developed. Omission of the tumor targeting ligands decreases the overall molecular weight of the theranostic agents, which can accelerate the rate of membrane penetration into tumor tissues. Additionally, the conjugation between fluorophores and drugs can improve the hydrophilicity of more polar drugs, which will increase the passive diffusion across the relatively nonpolar cell membrane.
Wender et al. presented three disulfide-based luciferintransporter conjugates (68a-c) to establish operationally facile methods to quantify drug-conjugate delivery, linker cleavage, and drug release in real time in cellular assays. 190 The disulfidecarbonate linkers of these conjugates were stable without affecting the rapid release of luciferin and drug (within minutes) in cells through disulfide cleavage. The half-lives of the conjugates (68a-c) were 3 h, 11 h, and 33 h, respectively, and depended on cyclization of the intermediate thiol with the carbonate. When the conjugates 68b and 68c were incubated with prostate tumor cells transfected with the luciferase gene, strong luminescence of luciferin could be observed within 1 min. Zhu and Guo et al. developed novel activatable theranostics (69a and 69b) based on the dicyanomethylene-4H-pyran NIR fluorophore for in vivo and in situ monitoring of drug delivery and cancer chemotherapy in living animals. 207 The biologically abundant thiols in tumor cells triggered cleavage of the View Article Online disulfide linker, leading to the release of camptothecin and emission of NIR fluorescence. These theranostics showed similar cytotoxicity with significant in vitro antitumor activity against several cell lines including BCap-37, HepG2, MCF-7, HeLa, KB, and KB200. However, the cytotoxicity of 69a was slightly higher than that of camptothecin and 2-fold lower than that of 69b. The prodrug 69a and its polyethylene glycol-polylactic acid (PEG-PLA)-encapsulated nanoparticles all displayed significantly potent cancer therapy and fewer side effects compared with free camptothecin. Loading of PEG-PLA nanoparticles increased the tumor localization properties and prolonged the plasma retention time of the prodrug. The theranostic prodrug 70 contained camptothecin and NIR cyanine dye, linked by a disulfide bond. 208 Cleavage of the disulfide bond resulted in generation of the active drug and induced a remarkable fluorescence shift. This change of wavelength provided dual fluorescent channels for real-time imaging of the activation and biodistribution process of the prodrug. After intravenous injection of 70 for 24 h, the prodrug predominantly accumulated and was activated in tumor lesions. Loading the theranostic prodrug in PEG-PLA nanoparticles would improve the therapeutic efficacy and reduce the side effects of comptothecin. 
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Chlorambucil (CLB) is a DNA alkylating agent that causes DNA damage in the nucleus. Zhou et al. developed a theranostic agent 71 composed of the potent anticancer drug CLB, a disulfide linker, and a fluorescent naphthalimide moiety. 209 The prodrug (Fig. 12 ).
Enzyme-activated release
Real-time detection of drug release would enable in vivo studies of pharmacokinetics, pharmacodynamics, and cell permeation pathways. A desirable activation mechanism for drug release depends on the unique physiologic characteristics of tumor cells. As various enzymes are typically overexpressed in tumor cells, utilization of overproduced enzymes as trigger switches for the development of enzyme-activated theranostics has been considered. Shabat et al. reported the prodrug system 76 containing a 7-hydroxycoumarin with a hydroxymethyl substituent spacer, the chemotherapeutic drug melphalan as the end-unit, and phenylacetamide as the cleavable linker. 218 The phenylacetamide could be cleaved by the enzyme penicillin-G-amidase (PGA) for release of drug in cells. In the presence of PGA, 76 exhibited cytotoxicity toward the cells with IC 50 of 2.5 mM. The prodrug 77 achieved selective activation in tumor cells. The proteolytic enzyme cathepsin B was employed to trigger the dipeptide Phe-Lys linker. 77 was more than 7.5-fold more toxic toward starved cells (IC 50 = 4 mM) than non-starved cells (IC 50 = 30 mM). The increased cytotoxicity of 77 was attributed to elevated expression of proteolytic enzymes, including cathepsin B. Human umbilical vein endothelial cells incubated with 77 showed cytoplasmic accumulation of activated coumarin. DT-diaphorase, a cytosolic flavoenzyme, plays essential roles in the cellular antioxidant system. DT-diaphorase levels are markedly higher in a number of tumor tissues than normal tissues. 219 DT-diaphorase has been employed as a trigger to activate quinone antitumor drugs and acts as a valuable biomarker for efficient drug delivery. 
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DT-diaphorase was developed to produce therapeutic NO by metabolizing a nitric oxide (NO) prodrug. 220 In addition, Wu et al. reported a DT-diaphorase-activatable theranostic prodrug 78. 221 78 was composed of an antitumor drug camptothecin (CPT), a self-immolative linker, and a quinone propionic acid trigger group. As a result of a photoinduced electron transfer (PET) process between CPT and the quinone propionic acid moiety, the fluorescence of CPT was almost quenched. After reduction by DT-diaphorase, the active CPT recovered its fluorescence emission. CPT release could be monitored by real-time detection of fluorescence. The prodrug exerted high cytotoxicity towards DT-diaphorase overexpressing cell lines. Indoleamine-2,3-dioxygenase (IDO) is an immunosuppressive enzyme present in human tumors that can be used as a tumor immunotherapeutic target. Lippard et al. were released inside tumor cells. The release of (D)-1-MT would enhance T-cell proliferation and the generation of cisplatin would concomitantly induce DNA damage in tumor cells. Dynamic blood stability experiments of 79b in Balb/c mice revealed t 1/2 of 1 h, and the human blood stability study showed t 1/2 of 2.2 h.
pH-triggered theranostics
The tumor cell micromilieu is highly acidic (pH 6.0-7.0), mainly as a result of glycolysis and hypoxia. 223 Growth of solid tumors requires large amounts of nutrients such as glucose; however, highly efficient glycolysis will induce intracellular acidification due to the generation of lactic acid. In addition, the extracellular diffusion effect of CO 2 is discharged by tumor tissue hypoxia, producing carbonic acid with H 2 O. Zhang et al. designed a pH-responsive prodrug (80) for realtime monitoring of drug release in the tumor mass. 224 The prodrug contains three parts: a coumarin fluorophore, a targeting moiety GRGDS oligo-peptide that can be recognized by a v b 3 integrin, and doxorubicin, which functioned not only as an antitumor drug but also as a fluorescent quencher for coumarin. The GRGDS moiety promoted selective uptake of the prodrug into tumor cells that overexpressed a v b 3 integrin. The hydrazone bond in the prodrug could be cleaved in the endosomes/lysosomes (pH 5-6) of tumor cells and the activated doxorubicin induced cell apoptosis. In addition, the fluorescence of coumarin was recovered. In vitro studies showed approximately 93.8% release of drug at pH 5.0 and only 40.7% release at pH 7.4. Merged fluorescence images indicated that this prodrug was internalized and cleaved in endo/lysosomes. Hanson et al. synthesized a therapeutic agent of steroidal anti-estrogen and doxorubicin (81) . 225 This prodrug reduced the side effects of doxorubicin and the targeted drug delivery of steroidal anti-estrogen improved its efficacy. Fluorescence microscopy studies in MCF-7 cells that overexpress the estrogen receptor (ER) suggested that the uptake process was controlled via a membrane ER-mediated mechanism, resulting in cellular accumulation of doxorubicin. Once the prodrug entered the acidic cytoplasm of tumor cells, hydrolysis of the pH-sensitive hydrazone linker released free doxorubicin to kill the tumor cells.
Light-activated theranostics
As an alternative to chemotherapy, a new modality termed photodynamic therapy (PDT) has been successfully applied in the clinic for the treatment of a variety of tumors and other diseases. 226 Photoresponsive theranostics allows precise control of drug release, including location, timing and dosage, through an active ''phototrigger''. 227 The primary components of photoresponsive theranostics include a photosensitizer, a masked drug, a photo-switched linker, light, and molecular oxygen. All of these elements are required in PDT to produce reactive oxygen species and release cytotoxic drugs for killing of tumor cells (Fig. 13) . Berkman et al. reported PSMA inhibitor conjugates of pyropheophorbide-a (82 and 83) for targeted photodynamic therapy of prostate tumors. 228, 229 Compared with PSMA-negative PC-3 cells, the prodrug 82 selectively induced apoptosis in PSMA-positive 
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LNCaP prostate tumor cells via in vitro targeted photodynamic therapy. Fluorescence labeling showed that conjugate 83 was specifically localized in PSMA-positive LNCaP cells, but not PSMA-negative PC-3 cells. Studies with specific caspase inhibitors revealed that conjugate 83 mediated apoptosis through the caspase-8/-3 pathway in PSMA-positive LNCaP cells; after 4 h of PDT treatment with 83 the activities of caspases-8, -9, and -3 were increased. Ju et al. reported a pH-activatable aniline-substituted azaboron-dipyrromethene as a photosensitizer for efficient photodynamic therapy and therapeutic monitoring (84) . 230 To achieve high accumulation in tumors, compound 84 was encapsulated in a cyclic RGD peptide-functionalized poly(ethylene glycol)-block-poly(lactic acid) and methoxyl poly(ethylene glycol)-blockpoly(lactic acid) nanomicelle (Fig. 14) . After activation by the physiologically acidic pH in the tumor, 84 exhibited strong phototoxicity by producing 1 O 2 and emitted fluorescence. The fluorescence at the tumor increased gradually and reached a maximum at 8 h post-injection. The high fluorescence level could be maintained for more than 16 h after injection.
Choi et al. developed a folate-photosensitizer conjugate (85) via a protein linker for photodynamic therapy. 231 The NIR fluorescence emission of the photosensitizer was quenched when folate was removed by the tumor-associated lysosomal enzyme cathepsin B. KB cells were implanted into mice as a xenograft model to assess the utility of conjugate 85 for in vivo fluorescence imaging and photodynamic therapy. Strong fluorescence signals were observed at the tumor site at 3 h post-injection and could be maintained for up to 24 h. You et al. synthesized three double activatable prodrugs of the CA-4, SN-38, and coumarin system (86a-c) that were first activated by intracellular esterase and then drug release was induced by light irradiation. 232 A photo-cleavable aminoacrylatelinker and a deactivated photosensitizer allowed the spatiotemporally controlled release of drugs by visible light irradiation. When the prodrug 86a was irradiated with very low intensity light (540 nm, 8 mW cm
À2
) for 30 min up to 99% of the coumarin was released.
NIR light has great potential for spatiotemporally controlled release of therapeutic agents due to its deep tissue penetration. You et al. demonstrated that the aminoacrylate group could be cleaved to release parent drugs after oxidation by 1 O 2 when activated by NIR light. 233 The prodrugs of combretastatin A-4 (87a-c) contain core-modified porphyrin as a NIR photosensitizer to generate 1 O 2 . The aminoacrylate linker of 87a was broken by tissue-penetrable NIR light (690 nm), releasing the antitumor drug. The prodrug 87a exhibited a significantly better antitumor effect after irradiation than 87b. The prodrug 87c was designed for in vivo fluorescence imaging after cleavage of the aminoacrylate group in mice. The prodrug 88a was developed to achieve multifunction activity, including the release of drug, fluorescence imaging, and photodynamic therapy. 234 The compound 88b was designed as a pseudo-prodrug to assess the effects of photodynamic therapy and confirm the potential application of the prodrug 88a in vivo. The time-dependent distribution of 88a was investigated using Balb/c mice with SC tumors (colon-26 cells, 4-6 mm in length). You et al. expanded their NIR light activatable strategy by integrating a tumor-targeting folic acid group into the prodrug systems (89a-e). 235 The photosensitizer and fluorophore was phthalocyanine. The light switch was aminoacrylate with variable polyethylene glycol chains. Compared with the lipophilic prodrugs 89a and 89b, the hydrophilic prodrugs 89c and 89d had higher cellular uptake in SC colon-26 tumors. The prodrug 89e without folic acid indicated the effectiveness of tumor targeting. Singh et al. 236 developed a targeted photoresponsive prodrug 90 containing biotinylated coumarin and chlorambucil, in which the phototrigger was directly attached to the drug. The prodrug 90 could be selectively taken up by MDA-MB-231 cells.
The release time of active chlorambucil was 20 min after light irradiation. Biotin-mediated accumulation could significantly increase the efficiency of intracellular drug delivery in the MDA-MB-231 cell line. The tropomyosin receptor kinase C (TrkC) receptor is normally expressed in neurons, but is overexpressed in highly metastatic tumor cells such as neuroblastoma, glioblastoma, thyroid cancer, melanoma, and breast cancer. [237] [238] [239] [240] [241] [242] [243] [244] The TrkC receptor could be used as a potential molecular target for chemotherapeutics. Burgess et al. reported fluorescence conjugates for PDT based on a synthetic peptidomimetic (including isoleucine and tyrosine side chains) targeting ligand. 245 Conjugate 91a composed of a peptidomimetic and a boron dipyrromethene (BODIPY) fluorophore for tumor imaging was selectively accumulated in TrkC receptor-expressing tumor tissues. Intracellular imaging studies showed that 91a was internalized into lysosomes, and behaved as the natural TrkC ligand neurotrophin-3 when internalized via the TrkC receptor. The diiodo-BODIPY could perform as a photosensitizer to produce triplet oxygen for PDT. Conjugate 91a induced significant photocytotoxicity in TrkC-expressing NIH-3T3 fibroblasts and SY5Y neuroblastoma cells compared with TrkC-negative cells. The biodistribution of conjugate 91a was tested in mice bearing 4T1 tumors. Fluorescence was maintained at a high level for up to 72 h after intravenous administration. The isomeric conjugate 91b that could not bind TrkC was used as a control probe. The application of PDT to lesions in deep tissue is often hampered by light penetration, as well as absorption and scattering by biological tissues. Wang et al. developed a PDT system in which the photosensitizer was activated by bioluminescence instead of an external light source. 246 In this PDT system, luminol (92a), hydrogen peroxide, and horseradish peroxidase were used as bioluminescent molecules. Cationic oligo (p-phenylene vinylene) (OPV, 92b) was used as the photosensitizer. The activation View Article Online mechanism was bioluminescence resonance energy transfer (BRET). The blue bioluminescence generated from luminol excited OPV to produce reactive oxygen species to kill cancer cells and pathogenic microbes. The cationic 92b could bind to the HeLa cell surface. This BRET system could function in deeper tissues.
Schnermann et al. reported NIR light-mediated cleavage of antibody-drug conjugate 93 based on cyanine photocages. 247 The conjugate includes a heptamethine cyanine fluorophore as the caging component, the drug combretastatin A4, and panitumumab (Pan), a clinical monoclonal antibody to the human epidermal growth factor receptor (EGFR). The fluorescence The photo-activated group (o-hydroxyl E-cinnamic ester) of the prodrug was modified using a hypoxic trigger 4-nitrobenzyl group, which was directly attached to the anticancer drug gemcitabine. In hypoxic MCF-7 cells, the hypoxic trigger was reduced by nitroreductase and underwent a 1,6-rearrangement-elimination reaction to remove the masked group. Subsequent UV irradiation would induce isomerization and intramolecular esterification processes leading to the formation of a coumarin fluorophore and the release of gemcitabine. The theranostic prodrug exhibited significant cytotoxicity against MCF-7 cells.
Aggregation-induced emission-based theranostics
Aggregation-induced emission (AIE) is a unique photophysical process that is induced by a series of silole or tetraphenylethene derivatives that are non-emissive in dilute solutions but become highly emissive in solid or aggregated states. 251 Fluorescent probes with AIE characteristics possess unparalleled advantages in biological detection compared with traditional fluorescent probes. On one hand, they can achieve brighter fluorescence as a result of more AIE active molecules binding to the target analytes without aggregation-induced fluorescence quenching. On the other hand, the feature of a drastic enhancement in the fluorescence intensity associated with an aggregation event can be used as a method of quantitative detection (Fig. 15) . Tang et al. presented a series of theranostic agents based on AIE characteristics (Fig. 16) . [252] [253] [254] The theranostic prodrug 96 was a targetable theranostic Pt(IV) prodrug for monitoring and assessing drug-induced cell apoptosis. 252 The targeting ligand was a cyclic arginine-glycine-aspartic acid (cRGD) tripeptide for intergrin a v b 3 that was overexpressed on the surface of tumor cells. The prodrug was a nontoxic Pt(IV) complex that was reduced to toxic Pt(II) in tumor cells. Asp-Glu-Val-Asp (DEVD)-conjugated tetraphenylsilole (TPS) that possessed AIE characteristics was used as an apoptosis sensor. The prodrug 96 selectively accumulated in tumor cells that overexpressed a v b 3 integrin and then released the toxic drug Pt(II) to induce apoptosis. Subsequently, caspase-3 cleaved the apoptosis unit TPS-DEVD and triggered the AIE fluorescence. A targeted theranostic Pt(IV) prodrug 97 based on an AIE luminogen for in situ monitoring activation of the platinum(IV) prodrug was developed. 253 The theranostic prodrug consisted of nontoxic Pt(IV) complexes, a tetraphenylethene pyridinium unit with AIE properties, a short hydrophilic peptide with five aspartic acid (D5) units to ensure its water solubility, and a cRGD tripeptide as the targeting ligand. Prodrug 97 could be selectively taken up by MDA-MB-231 cells that overexpressed a v b 3 integrin. The theranostic prodrug 98 contained a targeted cRGD moiety, a tetraphenylene (TPE) derivative, a fluorescent antitumor drug doxorubicin (DOX), and a chemotherapeutic Pt(IV) prodrug. 98 was selectively taken up by tumor cells that overexpressed a v b 3 integrin accompanied by the release of two drugs: Pt(II) and DOX. The fluorescence of TPE recovered, followed by the separation of TPE and DOX. 254 The outer membrane of mitochondria has a more negative potential in tumor cells. 255 Triphenyl phosphonium cation 
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(TPP) facilitates penetration of the phospholipid bilayers in mitochondria due to the positive charge on the phosphonium and three lipophilic phenyl groups. 256 Liu et al. presented a mitochondrial targeting probe (99) formed by conjugation of a salicyladazine fluorophore with the mitochondria-targeting TPP. 257 The fluorescence manipulation mechanism involved both AIE and excited-state intramolecular proton transfer processes, which could enhance the imaging contrast and the signalto-noise ratio. The probe exhibited no fluorescence in culture media but fluorescence was activated after its accumulation in the mitochondria of tumor cells. The probe could induce the generation of reactive oxygen species and affect essential cancer cell progression, leading to tumor cell apoptosis.
NIR dye-based theranostics
NIR hemicyanine dyes are desirable candidates for the development of fluorescence imaging probes due to their photophysical properties, biocompatibility, and low toxicity to living systems. 269 The derivatives 106c and 106d exhibited enhanced cytotoxicity toward all six cell lines tested: human cervical tumor HeLa, breast carcinoma MCF7, osteosarcoma U2OS, ovarian carcinoma A2780, and cisplatin-resistant ovarian carcinoma A2780-CP70 cells. The complex 106c was mainly targeted to mitochondria, whereas 106d was primarily located in the outer cellular membrane. The anticancer activity of 106c was similar to that of cisplatin. 106c exerted its toxicity through a mitochondria-related pathway. The mitochondrial membrane potential of tumor cells was impaired as early as 2 h after the introduction of 106c. Mao et al. designed three fluorescent Ru(II)-polypyridyl complexes 107a-c targeting histone deacetylase inhibitors (HDACs) as antitumor agents. 270 These antitumor agents showed relatively high quantum yields, large stokes shifts, and long emission life times. The fluorescence regulation mechanism was a metal-toligand charge transfer process. Treatment of HeLa cells with complex 107c significantly increased the acetylation of histone H3 in a dose-and time-dependent manner. Confocal microscopy images illustrated that 107c accumulated in the nuclei. Cell apoptosis induced by 107c was determined to involve mitochondrial dysfunction and the production of reactive oxygen species. The compounds 108a-c based on cyclometalated iridium(III) complexes, which included bis-N-heterocyclic carbene ligands as photodynamic and mitochondrial targeting groups, were also reported as theranostic agents. 271 All complexes were effectively localized in mitochondria and displayed higher cytotoxicity than cisplatin against all tested human tumor cell lines. The order of complexes for active transport with uptake was 108c 4 108b 4 108a. The mechanism for apoptosis was mitochondrial damage caused by overproduction of reactive oxygen species (Fig. 18) . Farrell et al. presented Ru complexes 109a-c and 110a,b, which showed high cellular and uptake antitumor activity. respectively, which indicated that the hydrogen bond of the imidazole units strongly affected antitumor activity. Fluorescence imaging indicated that 109a and 109b localized in the cytoplasm and in the nucleus, respectively. Flow cytometry and western blotting indicated that complex 109a inhibited the G1 and S phases of the cell cycle.
Che et al. developed a class of antitumor Au(III) complexes containing N-heterocyclic carbene and 2,6-bis(imidazol-2-yl)-pyridine or 2,6-bis(benzimidazol-2-yl)pyridine ligands (111a-g, 112a-c). 273 The biothiols reduced the Au(III) complexes to the Au(I) state with release of the fluorescent ligand. These Au(III) complexes could suppress tumor growth in mice bearing HeLa xenografts. 112a was easily taken up by cells and localized in the mitochondria of HeLa cells. 111e exhibited significant suppression of tumor volume in vivo.
Aptamer-based theranostics
Aptamers are structured single-stranded DNA or RNA molecules that have a high affinity for small molecules, peptides, proteins, and oligosaccharides. Therefore, aptamers have attracted great attention because of their potential application for therapeutic or diagnostic targeted-delivery. [274] [275] [276] [277] [278] [279] Fig . 18 Theranostics based on metal complexes and aptamers. 
Challenges and perspectives for optical chemical probes
This review focuses on small molecular ligand-targeted fluorescent imaging probes and fluorescent theranostics for tumor diagnosis and therapy. It does not include nanoparticles, polymers, or liposomes, even though small molecular targeting groups and/or cytotoxic drugs have been attached and loaded to these transport carriers. The general tumor treatment methods include surgery, radiotherapy and chemotherapy. However, surgery is the preferred modality for the treatment of most solid tumors. The primary challenge for surgical intervention is how to distinguish the surgical margin between the lesion and its healthy surrounding tissue at the cellular level. Fluorescence bioimaging technologies for delimiting the surgical margin are able to precisely discern diseased tissues in patients. With current fluorescence imaging instruments, fluorescent imaging probes can be exploited for intraoperative decisions concerning which tissues need to be resected and which tissues need to be preserved during surgery. Successful surgical fluorescent navigation for tumor lesions is achieved by significantly minimizing the background and maximizing the target-to-background ratio to increase contrast. The general requirements and objectives of imaging probes are designed to achieve optimal visualization. In general, there are two approaches for targeting imaging probes to tumor lesions ( Fig. 1 and 19) . Passive targeting benefits from the enhanced permeability and retention (EPR) effect, in which the defects or gaps in the tumor vasculature are typically 200 to 2000 nm in diameter. The EPR effect allows the extravasation and accumulation of both small molecules and larger particles (mainly with diameters o600 nm). Small molecules can easily diffuse back into the blood circulation by way of the defects or gaps, but larger particles (44 nm or 30 kDa) are retained in solid tumors. This effect results in the preferential accumulation of larger particles around tumors. However, deep penetration of larger particles is hampered by the dense tumor interstitial space. This tumor backpressure strongly misrepresents diffusion patterns of larger particles in solid tumors. Obstacles to tumor penetration originating from the tumor backpressure should be overcome, as small molecules can be released and integrated into the tumor independently. This strategy belongs to the second category of active targeting, which requires the involvement of targeting moieties such as ligands, peptides, proteins, and antibodies. These targeting moieties are used to implement the identifying features (i.e., tumor-specific receptors) that uniquely exist on the surface of tumor cells, such as proteins, sugars, and lipids. That is why the design focus for active targeting View Article Online is seeking the right targeting moiety. These imaging probes are often represented as targeting moiety-spacer-fluorophore conjugates (Fig. 20) . As the overall design approach, we first investigate the tumor-specific receptor that is the binding site of the imaging probes. To effectively capture the targeting moiety, the desirable receptor must meet the following criteria. First, the receptor is overexpressed on cancer cells. Relative to normal cells, the absolute level of the expressed receptor on cancer cells must be at least 3-fold higher. Second, the candidate receptor is fixed on the cell surface and should not be cleaved or shed into the circulation. Here, receptor-mediated endocytosis does not need to be considered. The critical need is a fluorescent imaging probe that accurately labels the tumor lesions. The candidate receptor is required to have a high affinity for the imaging probe, as this is a major contributing factor to the target-to-background ratio, tumor accumulation, and residence time. Any unbound imaging probe must be rapidly cleared by the circulation. If the targeted receptor is overexpressed within the cytoplasm or nucleus, the imaging conjugate should be designed to be nonspecifically permeable across cell membranes. The design of the targeting moiety must sufficiently take into account the affinity, specificity, molecular size, and functional-group modifiability. The dissociation constant (K d ) of the targeting moiety for its receptor is suggested to be lower than 10 nM. The spacer between the targeting moiety and the fluorophore via the derivatizable functional group must not severely reduce the affinity. The derivatizable functional group of the spacer is required to be chemically stable. Removal of the unbound imaging probe is controlled by the diffusion and clearance rate from the circulation. A NIR fluorophore is preferred for the selection of the fluorophore, in part because the low biological background is conducive to bioimaging. To date, fluorescent imaging probes that are applied to assist intraoperative dissection have been untargeted fluorescent dyes including methylene blue, indocyanine green, fluorescein, and 5-aminolevulinic acid. Although numerous targeting moiety-fluorophore conjugates have been reported only a few are in the process of clinical translation, such as IRDye 800CW, 281 ZW800-1, 282 EC17, 283 and OTL-0038. 95 In terms of increasing the target-to-background ratio, an activatable imaging probe is better than an active imaging probe due to the controllable change in fluorescence.
Anticancer drugs have made chemotherapy an indispensable therapeutic intervention for inhibiting the rapid growth of tumor cells. Chemotherapeutic drugs have achieved great advances, but their non-specific distribution in normal and tumor cells leads to low efficacy and severe side effects. Additionally, drug resistance is another factor that should be considered. The mechanisms of drug resistance involve sub-therapeutic concentrations and upregulation of efflux transporters and metabolizing enzymes. In order to improve the effectiveness of cancer treatment, it is essential to develop new strategies for the effective delivery of chemotherapeutic drugs to cancer cells. It seems that the targeted delivery of drugs can improve pharmacokinetics and increase efficacy. Passive targeting employs polymeric structures as carriers, such as nanoparticles, polymers, or liposomes. [284] [285] [286] [287] [288] [289] [290] [291] This strategy is highly dependent on the enhanced permeability and retention effect. The direct conjugation of a chemotherapeutic drug to a certain tumor cell targeting ligand represents active targeting. The structure of this kind of drug delivery system generally includes a targeting moiety linked to a potent chemotherapeutic drug via a linker that embodies a cleavable bond. 292 The above-mentioned targeted delivery strategies have provided great advantages over traditional non-targeted chemotherapeutic drugs. 292 However, the progression and treatment of tumors involves many complicated stages including initiation, progression, metastasis, recurrence, and resistance to therapy. A precise diagnosis is indispensable for tumor staging and early therapy. To meet this demand, diagnostics and therapeutics are being integrated to provide promising tools for tumor diagnosis and therapy (Fig. 19 ). This newly emerging combined system has been termed theranostics. Smallmolecule fluorescent theranostics are conceived and synthesized as three or four moieties. A targeting moiety is covalently labeled with a fluorophore via a spacer, and then a chemotherapeutic drug is introduced into the molecular structure through a cleavable linker. This can be represented as a targeting moiety-spacerfluorophore-linker-drug (Fig. 20) . For the design of smallmolecule fluorescent theranostics, the issues to be considered combine the requirements of both diagnostics and therapeutics. However, one must also pay attention to receptor-mediated endocytosis. The candidate receptors on the cell surface must be sufficient to meet the precise delivery of theranostics into tumor tissues. The theranostics are intended to be retained within the tumor cells and achieve the desired steady-state concentrations. Another focal point is the manipulation of drug release at tumor lesions because non-targeted drug release will result in systemic toxicity. Structural constraints on the introduction of chemotherapeutic drugs are often imposed by the linkers therefore the design of cleavable linkers using tumor factors is a key element for drug triggering release. The tumor physiological microenvironment is different from that of normal tissues. Insufficient and defective vascular structures of the tumors result in hypoxia, low pH, and high interstitial fluid pressure. Some other unique characteristics of tumors, such as high levels of reactive oxygen species, high concentrations of glutathione, as well as overexpressed enzymes, also act as advantageous stimulants. External stimulators, such as light and heat, are good releasing triggers. It is worth noting that no residues of the linker can remain in the released chemotherapeutic drug. In terms of the design requirements of the overall small-molecule fluorescent theranostic agents, they are expected to have low cytotoxicity, excellent pharmacokinetics, and chemical stability before reaching their destination. At the same time, we require the linker to play a role in regulation of the fluorescence changes that function as non-invasive, real-time, in situ, and direct detection signals. Theranostics have been developed to target the primary tumor and metastases for early diagnosis and therapy. After being specifically activated by tumor factors, the cytotoxic drugs are released to inhibit the growth of tumor cells. High accumulation in tumor lesions allows cytotoxic drugs to act as effectively as possible. These expected effects allow patients to be administered lower doses, thus reducing overall systemic toxicity. Fluorescence signals provide an imaging modality that can both address the tumor lesions (by overexpressed receptors) and directly indicate the administered drugs (for distribution and accumulation). Fluorescence imaging of theranostics can allow visual evaluation and normalization of the efficacies of targeted drugs at tumor lesions. The results facilitate drug development by offering more information on the tumor stage, targeting ability, pharmacokinetics, and dosage. To date, there are no small-molecule fluorescent theranostics in clinical trials.
Imaging technologies are essential for the detection and visualization of tumor lesions. Current clinical imaging modalities include positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging/ spectroscopy (MRI/MRS), computed tomography (CT), and ultrasound (US). Most of these have no depth sensitivity limit, but they cannot provide a real-time response for intraoperative diagnosis. Fluorescence imaging technology is expected to overcome some of the limitations of conventional therapeutics and improve tumor treatments. For fluorescence imaging tools, excellent selectivity and high sensitivity are the key parameters for visualizing physiological and pathological factors at a molecular level. These tools are also required to have sufficient spatial resolution for in vivo imaging. Unfortunately, the narrow tissue penetration of fluorescence has become the main obstacle to deep body scanning. Therefore, fluorescence imaging is performed at different spatial and temporal resolutions, ranging from micrometers (o5 mm) to centimeters (o10 cm). 48 Which imaging modality is chosen depends on the purpose of the examination and the site of the tumor lesion. To better understand the comprehensive nature of the tumor, development of this field has advanced toward combining fluorescence imaging with other radioactive imaging modalities, as well as intraoperative ultrasonography (termed as photoacoustic imaging). This strategy is expected to coordinate the individual benefits of each imaging technology, and thus overcome the limitations. In addition, attention must be paid to the cost and regulatory requirements for imaging reagents.
Conclusions
Cancer has been identified as a dominant cause of death. Surgery and chemotherapy drugs play vital roles in the treatment of tumors. Fluorescence imaging provides an exceptional approach to imaging and quantification of cellular dynamic events that have an enormous impact on the tumor. Fluorescence imaging is achieved by maximizing the target-to-background ratio. The availability of fluorescently labeled probes for targeting tumor lesions, including tumor margins, nerves, lymph nodes, and lymphatics, greatly benefit intraoperative diagnosis. Such small molecular fluorescent probe-based therapeutic systems, composed of an antitumor drug, an imaging unit, and a tumor targeting ligand linked by a cleavable bond, show high accumulation at tumor cells and low toxicity to normal cells. The therapeutic agents are responsive to physiological factors, such as GSH, H 2 O 2 , enzymes, and pH, and to external stimulators such as phototriggers to specifically release the incorporated prodrug. Such agents are not only used to examine the necessary dose and timing and the pharmacokinetics of chemotherapy drugs, but are also applied in real time to indicate the biodistribution and efficacy of chemotherapy drugs. Future generations of smart fluorescent imaging and theranostic agents should incorporate a specific tumor-targeting unit and cleavable bond to achieve enhanced cellular selectivity and targeted drug release. The ultimate goal of tumor therapy is to improve the quality of life and prolong the survival time.
